Related Experiment Video
Updated: May 12, 2026
11:15
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
10.1K
Osteosarcoma Cell and Osteosarcoma Stem Cell Potent Immunogenic Bi-Nuclear Gallium(III) Complexes
Xiao Feng1, Shruti Dhandore1, Yu Liu1
1School of Chemistry, University of Leicester, Leicester, LE1 7RH, UK.
Chemistry (Weinheim an Der Bergstrasse, Germany)
|April 9, 2025
Summary
New gallium(III) complexes show potent anti-cancer activity against osteosarcoma cells and stem cells (OSCs). These compounds effectively target 3D tumor structures and exhibit promising immunogenic properties, representing a novel therapeutic approach.
Area of Science:
- Inorganic Chemistry
- Medicinal Chemistry
- Cancer Biology
Background:
- Osteosarcoma is a primary bone cancer with limited treatment options.
- Current metallodrugs like cisplatin and carboplatin have significant limitations in treating osteosarcoma, especially its stem cell population.
- Osteosarcoma stem cells (OSCs) are crucial for tumor recurrence and metastasis.
Purpose of the Study:
- To synthesize and characterize novel bi-nuclear gallium(III) complexes.
- To evaluate the anti-cancer efficacy of these complexes against osteosarcoma cells and OSCs.
- To investigate the mechanism of action and immunogenic potential of the most effective gallium(III) complex.
Main Methods:
- Synthesis and characterization of bi-nuclear gallium(III) complexes with Schiff base ligands and 8-hydroxyquinoline.
- Monolayer and 3D sarcosphere cytotoxicity assays.
- Caspase-dependent apoptosis and paraptosis assays.
- Phagocytosis assays by immune cells.
Main Results:
- Gallium(III) complexes 1-4 demonstrated micromolar cytotoxicity against osteosarcoma cells and OSCs.
- Complex 2 showed superior potency against OSCs (up to 13-fold) and sarcospheres (up to 53-fold) compared to cisplatin and carboplatin.
- Complex 2 induced caspase-dependent apoptosis and paraptosis, leading to immunogenic cell death.
- Treated cells were effectively phagocytosed by immune cells, indicating significant immunogenic potential.
Conclusions:
- Bi-nuclear gallium(III) complexes exhibit potent anti-osteosarcoma and anti-OSC activities.
- These complexes show enhanced efficacy against 3D tumor structures, suggesting better drug penetration.
- Gallium(III) complex 2 is the first metal complex to demonstrate an immunogenic response against both bulk osteosarcoma cells and OSCs, offering a novel therapeutic strategy.
